OpenLB
Open Library of Bioscience
Advanced Search
Bone marrow transplantation
Aug, 2014;49 (8): 1113-5.

A higher number of infused CD34(+) cells has a positive impact on the clinical outcome after related PBSC transplantation.

K Maie, S Fuji, K Tajima, M Tatsuno, S Yamagata, N Takahashi, R Ueda, H Hashimoto, K Takano, Y Inoue, A Ito, Y Hayashi, K Okinaka, S Kurosawa, S-W Kim, R Tanosaki, Y Heike, T Yamashita, T Fukuda
Author Information
  1. K Maie: 1] Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan [2] Department of Hematology, University of Tsukuba, Tsukuba, Japan.
  2. S Fuji: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
  3. K Tajima: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
  4. M Tatsuno: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
  5. S Yamagata: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
  6. N Takahashi: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
  7. R Ueda: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
  8. H Hashimoto: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
  9. K Takano: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
  10. Y Inoue: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
  11. A Ito: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
  12. Y Hayashi: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
  13. K Okinaka: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
  14. S Kurosawa: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
  15. S-W Kim: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
  16. R Tanosaki: Department of Blood Transfusion and Cellular Therapy, National Cancer Center Hospital, Tokyo, Japan.
  17. Y Heike: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
  18. T Yamashita: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
  19. T Fukuda: Hematopoietic Stem Cell Transplantation Division, National Cancer Center Hospital, Tokyo, Japan.
PMID: 24797181 DOI: 10.1038/bmt.2014.94

Abstract

No abstract text available.

References

  1. Bone Marrow Transplant. 2008 Feb;41(3):245-52 [PMID: 17952129]
  2. Blood. 2009 Sep 24;114(13):2606-16 [PMID: 19608747]
  3. Bone Marrow Transplant. 2013 Mar;48(3):452-8 [PMID: 23208313]
  4. Leukemia. 2003 May;17(5):869-75 [PMID: 12750699]
  5. Bone Marrow Transplant. 2014 Jan;49(1):30-7 [PMID: 24056742]
  6. Br J Haematol. 2000 Feb;108(2):408-14 [PMID: 10691874]
  7. Blood. 2002 Apr 15;99(8):2726-33 [PMID: 11929759]
  8. Bone Marrow Transplant. 2012 Dec;47(12):1564-8 [PMID: 22609881]
  9. Biol Blood Marrow Transplant. 2008 Apr;14(4):449-57 [PMID: 18342788]

MeSH Term

Adult
Age Factors
Aged
Allografts
Antigens, CD34
Female
Hematologic Neoplasms
Humans
Male
Middle Aged
Peripheral Blood Stem Cell Transplantation
Retrospective Studies
Transplantation Conditioning

Chemicals

Antigens, CD34
Clinical Trial Letter Research Support, Non-U.S. Gov't

Word Cloud

Created with Highcharts 10.0.0highernumberinfusedCD34+cellspositiveimpactclinicaloutcomerelatedPBSCtransplantation

Similar Articles

Cited By